The estimated Net Worth of John J Shea is at least $923 Tisíc dollars as of 13 August 2015. John Shea owns over 20,000 units of Biodelivery Sciences International stock worth over $297,975 and over the last 20 years John sold BDSI stock worth over $624,887.
John has made over 8 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently John exercised 20,000 units of BDSI stock worth $111,800 on 13 August 2015.
The largest trade John's ever made was exercising 130,000 units of Biodelivery Sciences International stock on 24 January 2014 worth over $510,900. On average, John trades about 19,150 units every 196 days since 2004. As of 13 August 2015 John still owns at least 53,305 units of Biodelivery Sciences International stock.
You can see the complete history of John Shea stock trades at the bottom of the page.
John's mailing address filed with the SEC is 90 POTESKEET TRAIL, , KITTY HAWK, NC, 27949.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott a Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: